Scientists in Japan develop plastic that dissolves in seawater within hours
By Irene Wang
WAKO, Japan (Reuters) -Researchers in Japan have developed a plastic that dissolves in seawater within hours, offering up a potential solution for a modern-day scourge polluting oceans and harming wildlife.
While scientists have long experimented with biodegradable plastics, researchers from the RIKEN Center for Emergent Matter Science and the University of Tokyo say their new material breaks down much more quickly and leaves no residual trace.
At a lab in Wako city near Tokyo, the team demonstrated a small piece of plastic vanishing in a container of salt water after it was stirred up for about an hour.
While the team has not yet detailed any plans for commercialisation, project lead Takuzo Aida said their research has attracted significant interest, including from those in the packaging sector.
Scientists worldwide are racing to develop innovative solutions to the growing plastic waste crisis, an effort championed by awareness campaigns such as World Environment Day taking place on June 5.
Plastic pollution is set to triple by 2040, the UN Environment Programme has predicted, adding 23-37 million metric tons of waste into the world's oceans each year.
"Children cannot choose the planet they will live on. It is our duty as scientists to ensure that we leave them with best possible environment," Aida said.
Aida said the new material is as strong as petroleum-based plastics but breaks down into its original components when exposed to salt. Those components can then be further processed by naturally occurring bacteria, thereby avoiding generating microplastics that can harm aquatic life and enter the food chain.
As salt is also present in soil, a piece about five centimetres (two inches) in size disintegrates on land after over 200 hours, he added.
The material can be used like regular plastic when coated, and the team are focusing their current research on the best coating methods, Aida said. The plastic is non-toxic, non-flammable, and does not emit carbon dioxide, he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
SpaceX will decommission Dragon spacecraft, Musk says as feud with Trump escalates
(Reuters) -Elon Musk's rocket company SpaceX will begin decommissioning its Dragon spacecraft immediately, the billionaire said on Thursday in response to U.S. President Donald Trump's statement that the government should cancel Musk's federal contracts. NASA relies on SpaceX's Dragon spacecraft to ferry astronauts to and from the International Space Station under a contract worth roughly $4.9 billion. The capsule is the only U.S. spacecraft capable of flying humans in orbit. Musk's statement marks a dramatic escalation in an intensifying fight with Trump that burst into public view this week, when Musk opposed the Trump administration's linchpin spending bill. Taking Dragon out of service would disrupt the ISS program, which involves dozens of countries under an international agreement signed over two decades ago. Russia's Soyuz system is the only other crewed spacecraft that sends astronauts to the ISS.
Yahoo
7 hours ago
- Yahoo
Japan's ispace says still unable to establish communication with moon lander after touchdown attempt
TOKYO (Reuters) -Japanese company ispace said it has not been able to establish communication with its uncrewed moon lander Resilience after its lunar touchdown attempt on Friday. Two years after its failed inaugural mission, Resilience was on ispace's second mission in a bid to become the first company outside the United States to achieve a moon landing. The company's live-streamed flight data showed Resilience's altitude suddenly falling down to zero shortly before the planned touchdown time of 4:17 a.m. on Friday, Japanese time (1917 GMT on Thursday) following an hour-long descent from lunar orbit.
Yahoo
7 hours ago
- Yahoo
US COVID vaccine recommendations sow confusion among doctors, insurers
By Julie Steenhuysen and Amina Niasse CHICAGO (Reuters) -Health Secretary Robert F. Kennedy Jr.'s intervention in COVID-19 vaccine recommendations without input from a key U.S. CDC advisory panel has sown confusion among physicians and insurers over who should get the shots and whether they will be covered, experts told Reuters. Kennedy, a long-time vaccine skeptic, in a video posted on social media last week said the government was dropping its recommendation that healthy children and pregnant women should receive COVID shots. Days later, the Centers for Disease Control and Prevention updated its recommended childhood vaccine schedule online to show the shots could be given to healthy children when parents and doctors agree they are needed. It removed its recommendation that pregnant women should receive the shot. The moves sidestepped the normal process in which a panel of outside experts to the CDC - the Advisory Committee on Immunization Practices - reviews data in a public meeting and votes on vaccine recommendations. The ACIP recommendations are sent to the CDC director for approval and incorporated in the agency's vaccine schedule, which helps determine insurance coverage under the Affordable Care Act. "The surprise announcement has created uncertainty for payers and providers about whether the video posting constitutes an official policy change," said Sarah Moselle, a principal at health consultancy Avalere. Insurers will wait to make coverage decisions until after ACIP makes a recommendation at its upcoming meeting scheduled for June 25-27, according to Robert Popovian, founder of healthcare consultancy Conquest Advisors. The Department of Health and Human Services overseen by Kennedy said the move was within its legal and regulatory authority and reflects the agency's move toward clinical-guided decision making, a department spokesperson said. HHS will continue to rely on the work of expert panels, including ACIP, he said, noting that the committee will be meeting this month. The meeting agenda will be released in accordance with prior practice. Determinations on coverage are up to insurance providers, the spokesperson said. The CDC has previously recommended the COVID shot for everyone aged 6 months and older. 'AWAITING CLARITY' "This whole thing is so murky," said an ACIP member who spoke on condition of anonymity. "It's very unclear whose decision is final." Infectious Diseases Society of America President Dr. Tina Tan said the conflicting COVID vaccine guidance could cause "significant confusion among medical professionals and the public." Dr. Matthew Zahn, an Orange County, California, public health official at OC Health Care Agency who serves as a liaison to the CDC's advisory panel, said: "We're all awaiting clarity." "It's going to be important to understand how these vaccines are insured," Zahn said. "Specifically, if ultimately there is a recommendation for high-risk populations to be vaccinated, how that is interpreted by insurance companies and thus, how providers can recommend it." Zahn expects CDC to clarify its guidance in the weeks ahead, though he could not comment on whether that will be at the ACIP meeting. On Tuesday, Reuters reported that pediatric infectious disease expert Dr. Lakshmi Panagiotakopoulos, a CDC official who helped oversee the expert panel on COVID vaccines, told colleagues she was leaving her post as she was "no longer able to help the most vulnerable members" of the U.S. population. The American College of Obstetricians and Gynecologists raised concerns on May 27 that the HHS decision not to recommend COVID vaccines during pregnancy would make it harder for pregnant women to get the shot "despite the clear and definitive evidence demonstrating its benefit." The Affordable Care Act generally requires insurers to cover vaccines that are listed on ACIP's vaccine schedule, according to the CDC's website. Narrowing coverage without knowing what ACIP recommends could put insurers at risk, Popovian said. "It's a liability," he said, adding that insurers need clarity on what they will be required to cover. A source familiar with plans for the meeting said the panel is expected to consider and vote on COVID-19 vaccines for the upcoming autumn and winter season, adding that the panel had been leaning toward narrowing its recommendations. The advisory panel has yet to receive an agenda for the upcoming meeting, the source said, and it is unclear whether Kennedy would override any deviation from his announced policy.
